“I buy on the assumption that they could close the market the next day and not reopen it for five years.”
— Warren Buffett
A five-year buy-and-hold investment in Charles River Laboratories International Inc. (NYSE: CRL) produced a negative total return over the period examined here. Based on the share prices shown below, a $10,000 investment made on 10/12/2021 would have declined to $7,396.30 by 10/09/2026, reflecting a loss driven entirely by share-price performance, as Charles River Laboratories does not pay a dividend in this calculation.
The result offers a useful case study in long-term equity returns: even companies with established operating franchises can generate disappointing investment outcomes when purchased at elevated valuations, when earnings expectations reset lower, or when end-market conditions weaken over time. In Charles River Laboratories’ case, the five-year holding period did not offset the stock’s decline from the starting price.
CRL 5-Year Return Details
| Start date: | 10/12/2021 |
|
|||
| End date: | 10/09/2026 | ||||
| Start price/share: | $408.03 | ||||
| End price/share: | $301.79 | ||||
| Starting shares: | 24.51 | ||||
| Ending shares: | 24.51 | ||||
| Dividends reinvested/share: | $0.00 | ||||
| Total return: | -26.04% | ||||
| Average annual return: | -5.86% | ||||
| Starting investment: | $10,000.00 | ||||
| Ending investment: | $7,396.30 | ||||
What Happened to a $10,000 Investment in Charles River Laboratories?
From 10/12/2021 through 10/09/2026, Charles River Laboratories stock fell from $408.03 to $301.79 per share. An initial purchase of 24.51 shares would therefore still amount to 24.51 shares at the end of the period, because no dividends were paid and no reinvestment occurred. The ending value of $7,396.30 implies a cumulative loss of 26.04%.
On an annualized basis, the investment returned -5.86%. That figure matters because annualized returns make it easier to compare this holding period with alternative uses of capital over the same span, including broader equity benchmarks, fixed income, or cash-equivalent yields available during portions of the period.
Why Total Return Was Driven Solely by the Stock Price
Charles River Laboratories is not typically owned for dividend income. The company’s investment case has historically centered more on revenue growth, margin execution, research-services demand, and strategic positioning in the biopharma development ecosystem than on capital returns through dividends. In this example, that means the full investment result came from the movement in the share price alone.
That distinction is important. For dividend-paying stocks, cash distributions can partially cushion periods of weak price performance. For non-dividend-paying stocks such as CRL in this analysis, the investor outcome depends much more directly on the entry valuation, the company’s earnings trajectory, and the market multiple assigned at the end of the holding period.
Key Takeaways From This 5-Year Holding Period
The five-year result highlights several broader points about long-term stock investing:
- Time horizon does not eliminate downside. Extending the holding period can reduce the impact of short-term volatility, but it does not guarantee a positive return.
- Entry price matters. Buying a strong business at an aggressive valuation can weigh on future returns even if the underlying company remains fundamentally relevant.
- Non-dividend stocks rely more heavily on execution. Without income distributions, shareholder returns depend primarily on earnings growth and valuation support.
- Total return is the proper lens. Looking only at the stock chart can miss the role of dividends or reinvestment, though in CRL’s case those factors were not present.
Bottom Line
The five-year buy-and-hold outcome for Charles River Laboratories was negative: $10,000 declined to $7,396.30, for a total return of -26.04% and an annualized return of -5.86%. That performance underscores a basic reality of equity investing: a long holding period can be a useful discipline, but the eventual result still depends on business performance, valuation, and the price paid at the outset.
[These numbers were computed with the Dividend Channel DRIP Returns Calculator.]
One final investing principle remains relevant here:
“The key to investing is not assessing how much an industry is going to affect society, or how much it will grow, but rather determining the competitive advantage of any given company and, above all, the durability of that advantage.” — Warren Buffett
